Musculoskeletal Health in Europe Juvenile Idiopathic Arthritis.

Slides:



Advertisements
Similar presentations
Psoriatic Arthritis Emily Chang Morning Report August 14, 2009 August.
Advertisements

FROM EUROCHIP-1 TO EUROCHIP-2 EUROCHIP-2 - The action Public Health Program EUROPEAN COMMISSION: HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL.
Spondyloarthropathies John Imboden MD
May 2014 Uveitis and HLA B27 Carol Slight Nurse Practitioner Ophthalmology.
Overview of Juvenile Idiopathic Arthritis
Antinuclear Antibody, Rheumatoid Factor, and Cyclic-Citrullinated Peptide Testing for the Evaluation of Musculoskeletal Complaints in Children Prepared.
Keynote address: Musculoskeletal conditions as a challenge for policy making Professor Paul Emery President of EULAR Professor of Rheumatology, University.
Musculoskeletal Health in Europe Health inequalities and musculoskeletal conditions.
Juvenile Rheumatoid Arthritis B. Paul Choate, M.D.
EPIDEMIOLOGY. General Prevalence of Joint Pain Age-sex adjusted to the 2000 United States (US) standard population. Source: National Health Interview.
European Heart Health Charter Official Launch 12 June 2007 European Parliament - Brussels "Every child born in the new millennium has the right to live.
Psoriatic Arthritis Maggie Davis Hovda Am report 2/16/2010.
The Child With Joint Pain Diagnostic Clues
Musculoskeletal Health in Europe Impact on society.
A Guide to Rheumatoid Arthritis for Legislators Rheumatoid Arthritis Policy Resource Center.
Psoriatic Arthritis Clinical Features and Epidemiology
Seronegative Spondyloarthropthies
Psoriatic arthritis – definition and classification criteria Philip Helliwell Senior Lecturer in Rheumatology University of Leeds.
Kathy Bailey Consultant Paediatric Rheumatologist Coventry and Warwickshire.
Selected causes of joint pain in childhood Infection ]Bacterial osteomyelitis± septic arthritis ] Mycobacterium ] Post viral (rubella, EBV, hepatitis.
Brief Overview of the Spondyloarthropathies
JRA is the most frequent chronic arthritis of children. The evidence of its was discovered from remained skeleton from 1000 years ago. It was prescribed.
Arthritis Facts. Leading Causes of Disability Among U.S. Adults, 1999 Among U.S. Adults, 1999 Arthritis is the leading cause of disability in the United.
Yackov Berkun, Hadassah Mnt Scopus Rheumatic diseases in children.
Overview of Arthritis Brought to you in collaboration by: 1. Arthritis Foundation Tennessee Chapter 2. Tennessee Department of Health 3. University of.
The Child With Joint Pain Diagnostic Clues Abraham Gedalia, M.D. Professor of Pediatrics Head, Division of Rheumatology Departments of Pediatrics, Louisiana.
 The Juvenile Arthritis Foot Disability Index (JAFI) (Andre et al, 2004) was the primary outcome measure of the impact of JIA on the foot.  The Child.
BOARD REVIEW RHEUMATOLOGY Dennis A. Peacock April 9, 2008.
The Arthritides Alexandra Hayes. An arthritide is when a person has a type of Arthritis. Arthritis occurs when there is inflammation of one or more joints.
March 22,  Most common organism?  Staph Aureus  Presentation?  Acute  Monoarthritis  Erythema  Warmth  Swelling  Intense pain.
ANKYLOSING SONDYLITIS
AM Report 11/24/09 Amy Auerbach  Peak onset between 20 and 30 years  Form of spondyloarthritis (cause inflammation around site of ligament insertion.
Seronegative Spondyloarthropathies
FONDE : A major new international research initiative (Marseille)
Statistics about unknown primary tumors Riccardo Capocaccia National Centre for Epidemiology, Surveillance and Health Promotion Istituto Superiore di Sanità,
Presenter: U. Rothe/ U. Manuwald Institution: 3 rd WP7 meeting Istituto Superiore di Sanità, Roma July, 2-3, 2015 Questionnaire on Prevention and Management.
Case Discussion Dr. Raid Jastania. What is the outcome of inflammation?
Health Examination Surveys in Europe Hanna Tolonen National Public Health Institute, Finland.
Spondyloarthropathies. Introduction Spondyloarthropathy (Spondloarthritis) – Term for a group of chronic diseases – Affecting the joints of the spine.
Arthritis Facts. Leading Causes of Disability Among U.S. Adults, 1999 Among U.S. Adults, 1999 Arthritis is the leading cause of disability in the United.
Nomenclature and classification of rheumatic diseases INFLAMMATORY JOINT DISEASES Rheumatoid arthritis Diseases of connective tissue ( SLE, Antiphospholipid.
Infectious arthritis Bacterial Viral Other Postinfectious (reactive) arthritis Rheumatic fever Reactive arthritis Enteric infection Other seronegative.
 Juvenile idiopathic arthritis (JIA) is the most common form of childhood arthritis and one of the more common chronic childhood illnesses. As the term.
Mary O’Hara Dr Margaret Hodgins PhD Study: Department of Health Promotion National University of Ireland, Galway 4th April 2011 Contact Details: e.mail:
Table 1. Criteria for differentiating acute and chronic hepatitis C Suggested citation: European Centre for Disease Prevention and Control. Annual epidemiological.
Recommendation 1: Defining & Diagnosing UPIA. Learning Objectives State the definition of Undifferentiated Peripheral Inflammatory Arthritis (UPIA) Describe.
Juvenile Idiopathic arthritis and infectious arthritis 郭三元 Division of R-I-A TSGH.
Table 1. Criteria for differentiating acute and chronic hepatitis B Suggested citation: European Centre for Disease Prevention and Control. Annual epidemiological.
Identifying Early Inflammatory Arthritis
Juvenile Idiopathic Arthritis
HLA-B27 Associated Anterior Uveitis
AS – the facts! Andrew Keat.
Dr.Khudair Al-bedri Consultant Rheumatology & Internal Medicine .
Juvenile Idiopathic Arthritis
Ankylosing Spondylitis
Musculoskeletal Health in Europe
Ankylosing Spondylitis
JUVENILE IDIOPATHIC ARTHRITIS
IMPORTANT SYSTEMIC ASSOCIATIONS OF UVEITIS
Albarouni, Mohammed 1, Becker, Ingrid 2, Horneff, Gerd 1
Enteropathic Arthropathy
Uveitis in the Spondyloarthropathies
What on earth is Spondyloarthritis
Trends for ECDC measles and rubella monitoring,
Bold diamonds are the mean percentage of time with inactive disease during the first 12 months within the subgroup. Bold diamonds are the mean percentage.
Dr Sarah Levy Consultant Rheumatologist CUH
common rheumatologic diagnoses
Presentation transcript:

Musculoskeletal Health in Europe Juvenile Idiopathic Arthritis

Juvenile idiopathic arthritis (JIA) Definition: Juvenile idiopathic arthritis = arthritis of unknown etiology that begins before the 16th birthday and persists for at least 6 weeks. Other known conditions are excluded.

Practitioner- or register-based study Incidence per 100,000 Savolainen, Finland, Pruunsild, Estonia, Berntson, Norway, Finland, Sweden, Denmark, Iceland, Riise, Norway, Hanova, Czech Republic, Modesto, Spain, Danner, France, JIA - Incidence

JIA – Age at Disease Onset % 5% 10% 15% 20% 25% 30% 35% Systemic arthritis Psoriatic arthritis Enthesitis-related arthritis Rheumatoid factor negative polyarthritis Age at onset in years Oligoarthritis Rheumatoid factor positive polyarthritis

Practitioner- or register-based study Prevalence per 100,000 Pruunsild, Estonia, Hanova, Czech Republic, Modesto, Spain, Danner, France, Solau-Gervais, France, JIA - Prevalence

JIA - Categories Oligoarthritis Rheumatoid factor negative polyarthritis Enthesitis-related arthritis Psoriatic arthritis Systemic arthritis (Still´s disease) Rheumatoid factor positive polyarthritis 52% 16% 15% 5% 4% Patients with recent onset JIA

JIA-categoryHLA-alleles conferring susceptibility Protective alleles Systemic arthritisDRB1*04, DRB1*11, DQA1*05- Oligoarthritis A2, DRB1*01, DRB1*08, DRB1*11, DRB1*13, DPB1*02, DQA1*04, DQB1*04 DRB1*04, DRB1*07, DQA1*03 Seronegative PolyarthritisA2, DRB1*08, DQA1*04, DPB1*03- Seropositive PolyarthritisDRB1*04, DQA1*03, DQB1*03DQA1*02 Psoriatic arthritisDRB1*01, DQA1*0101 DRB1*04, DQA1*03 Enthesitis-related arthritisB27, DRB1*01, DQA1*0101, DQB1*05- JIA - HLA associations

Definition: Arthritis affecting one to 4 joints during the first 6 months of disease. Two subcategories are recognized: 1. Persistent oligoarthritis: affecting not more than 4 joints throughout the disease course 2. Extended oligoarthritis: affecting a total of more than 4 joints after the first 6 months of disease JIA - Oligoarthritis

 Joints:1 joint with arthritis 1 joint with limited range of motion  Function:CHAQ-score 0.63 (median)  Eyes:4% uveitis  Lab:ESR 17 mm/h, CrP 7 mg/l (mean) 60-70% ANA, 0% RF Phenotype at onset: JIA - Oligoarthritis

Course and outcome: After 5 yearsPersistent OAExtended OA Percentage of patients2/31/3 (up to 50%) After 15 years Patients in remission, % Functional limitations (HAQ>0), % 2247 Frequency of erosions, % 533

JIA - Rheumatoid factor negative polyarthritis Definition: Polyarthritis (Rheumatoid Factor [RF] Negative) Arthritis affecting 5 or more joints during the first 6 months of disease A test for RF is negative ICD10-Code: M08.3

JIA - RF negative polyarthritis Phenotype at onset:  Joints:9 active joints and 6 with LOM  Function:CHAQ 1.25 (median)  Eyes:3% uveitis  Lab:ESR 22 mm/h, CrP 14 mg/l (median) 40-70% ANA, 0% RF

JIA - RF negative polyarthritis

Course and outcome: Follow-up > 10 years Patients in remission, %15-30 Patients with functional limitations (HAQ>0), % 47 Prevalence of erosions, % 40-75

JIA - Enthesitis related arthritis Definition: Arthritis and enthesitis, or arthritis or enthesitis with at least 2 of the following: 1. The presence of or a history of sacroiliac joint tenderness and/or inflammatory lumbosacral pain 2. The presence of HLA-B27 antigen 3. Onset of arthritis in a male over 6 years of age 4. Acute (symptomatic) anterior uveitis 5. History of ankylosing spondylitis, enthesitis related arthritis, sacroiliitis with inflammatory bowel disease, Reiter’s syndrome, or acute anterior uveitis in a first- degree relative

JIA - Enthesitis related arthritis Phenotype at onset:  Joints:2 active joints and 2 with LOM  Function:CHAQ 0.56 (median)  Eyes:9% uveitis  Lab:ESR 10 mm/h, CrP 3 mg/l (median) 20% ANA, 0% RF

JIA - Enthesitis related arthritis Course and outcome: Follow-up > 10 years Patients in remission, %17-44 Patients with functional limitations (HAQ>0), % 47 Prevalence of sacroiliits, % 35

JIA - Psoriatic arthritis Definition: Arthritis and psoriasis, or arthritis and at least 2 of the following: 1. Dactylitis 2. Nail pitting or onycholysis 3. Psoriasis in a first-degree relative ICD10-Code: M09.0*, L40.5 †

JIA - Psoriatic arthritis Phenotype at onset:  Joints:3 active joints and 2 with LOM  Function:CHAQ 0.56 (median)  Eyes:3% uveitis  Lab:ESR 26 mm/h, CrP 7 mg/l 45% ANA, 0% RF

JIA - Psoriatic arthritis Course and outcome: 68% oligoarticular onset  65% polyarticular course Outcome after > 15 years Patients in remission off medication (> 1 year), %55 Patients with functional limitations (HAQ>0), % 45 Prevalence of erosions, % 23

JIA - Systemic arthritis Definition: Arthritis in one or more joints with or preceded by fever of at least 2 weeks’ duration that is documented to be daily (“quotidian”) for at least 3 days, and accompanied by one or more of the following: 1. Evanescent (non-fixed) erythematosus rash 2. Generalized lymph node enlargement 3. Hepatomegaly and/or splenomegaly 4. Serositis

JIA - Systemic arthritis Phenotype at onset:  Joints:2 active joints and 0 with LOM  Function:CHAQ 1.0 (median)  Eyes:0% uveitis  Lab:ESR 93 mm/h, CrP 98 mg/l (median) 15% ANA, 0% RF

JIA - Systemic arthritis Complications: Macrophage activation syndrome % Growth failure20-41% Osteopenia/osteoporosis 0-7.5% Amyloidosis 1.4-9%

JIA - Systemic arthritis Course: 42% monocyclic  remission within 2-4 years 7% relapsing  flares of systemic features and mild arthritis 51% persistent  chronic progressive polyarthritis

JIA - Systemic arthritis Follow-up > 10 years Patients in remission, %20-76 Patients with functional limitations (HAQ>0), % 47 Prevalence of erosions, % Course and outcome:

JIA - Rheumatoid factor (RF) positive polyarthritis Definition: Polyarthritis (RF positive) Arthritis affecting 5 or more joints during the first 6 months of disease 2 or more tests for RF at least 3 months apart during the first 6 months of disease are positive ICD10-Code: M08.0

JIA - RF positive polyarthritis Phenotype at onset:  Joints:9 active joints and 7 with LOM  Function:CHAQ 1.0 (median)  Eyes:0% uveitis  Lab:ESR 15 mm/h, CrP 12 mg/l (median) 55% ANA, 100% RF

JIA - RF positive polyarthritis Course and outcome: Follow-up > 10 years Patients in remission, %0-46 Patients with functional limitations (HAQ>0), % 46 Prevalence of erosions, % 39-77

JIA - Estimated annual health care cost per patient (in Euro) Study Patients (n) Biologic drugs Health care cost (in €)Cost components Minden et al. Germany, 1999 JIA (215) 0%1,800 (mean) Medication: 15% Inpatient care: 55% Haapasaari et al. Finland, 2000 JIA (31) 100% 27,700 (median) converted from 2000 US$ Medication: 56% Inpatient care: n.r. Minden et al, Germany, 2003 JIA (369) 6%4,200 (mean) Medication: 47% Inpatient care: 39% Thornton et al. U.K., 2005 JIA (297) n.r.2,400 (mean) Medication: 11% Inpatient care: 0%

JIA - Estimated annual total cost per patient (in Euro) 02,0004,0006,0008,000 cost (€) Functional limitation (CHAQ) Disease activity (NRS) Pain intensity (NRS) moderate/severe mild none p = p < p = 0.020

JIA - mortality in children entire JIA group (90/2,076) 4% systemic JIA (84/611) 14% 1990 entire JIA group (33/11,287) 0.29% systemic JIA 3% 2010entire JIA group (19/9,604) 0.2%

JIA - mortality SMR 5.1 women (95% CI ) 3.4 men (95% CI )  4-fold increase in mortality in JIA compared to the general population in adults

JIA - malignancy Malignancy n Standardized rate (per 100,000 p-ys) SIR (95% CI) Simard et al., 2010, Sweden JIA: 13 cases/5,296 Controls: 30/26,480n.r.* 2.3 ( ) Beukelman et al. 2010, U.S. JIA: < 11 cases/7, ADHS: 63/308,45423 Asthma: 183/23,66327 Bernatsky et al., 2011, Canada JIA: 1 case/1,843 General population (0-0.7)

eumusc.net is an information and surveillance network promoting a comprehensive European strategy to optimise musculoskeletal health. It addresses the prevention and management of MSC’s which is neither equitable nor a priority within most EU member states. It is focused on raising the awareness of musculoskeletal health and harmonising the care of rheumatic and musculoskeletal conditions. It is a 3 year project that began in February It is supported by the European Community (EC Community Action in the Field of Health ), the project is a network of institutions, researchers and individuals in 22 organisations across 17 countries, working with and through EULAR. eumusc.net: creating a web-based information resource to drive musculoskeletal health in Europe Disclaimer The Executive Agency for Health and Consumers is not responsible for any use that is made of the information contained within this publication